These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 25824313

  • 1. Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control.
    Atwell TD, Vlaminck JJ, Boorjian SA, Kurup AN, Callstrom MR, Weisbrod AJ, Lohse CM, Hartman WR, Stockland AH, Leibovich BC, Schmit GD, Thompson RH.
    J Vasc Interv Radiol; 2015 Jun; 26(6):792-9. PubMed ID: 25824313
    [Abstract] [Full Text] [Related]

  • 2. Percutaneous Cryoablation of Clinical T2 (> 7 cm) Renal Masses: Technical Considerations, Complications, and Short-Term Outcomes.
    Moynagh MR, Schmit GD, Thompson RH, Boorjian SA, Woodrum DA, Curry TB, Atwell TD.
    J Vasc Interv Radiol; 2015 Jun; 26(6):800-6. PubMed ID: 25840835
    [Abstract] [Full Text] [Related]

  • 3. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses.
    Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, Psutka SP, Stewart SB, Callstrom MR, Cheville JC, Boorjian SA, Leibovich BC.
    Eur Urol; 2015 Feb; 67(2):252-9. PubMed ID: 25108580
    [Abstract] [Full Text] [Related]

  • 4. Percutaneous cryoablation of solitary sporadic renal cell carcinomas.
    Schmit GD, Thompson RH, Kurup AN, Weisbrod AJ, Carter RE, Callstrom MR, Atwell TD.
    BJU Int; 2012 Dec; 110(11 Pt B):E526-31. PubMed ID: 22584010
    [Abstract] [Full Text] [Related]

  • 5. Percutaneous Cryoablation of Solitary, Sporadic Renal Cell Carcinoma: Outcome Analysis Based on Clear-Cell versus Papillary Subtypes.
    Haddad MM, Schmit GD, Kurup AN, Schmitz JJ, Boorjian SA, Geske J, Thompson RH, Callstrom MR, Atwell TD.
    J Vasc Interv Radiol; 2018 Aug; 29(8):1122-1126. PubMed ID: 29887184
    [Abstract] [Full Text] [Related]

  • 6. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
    Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA.
    Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Percutaneous Cryoablation of Renal Tumors: Is It Time for a New Paradigm Shift?
    Aoun HD, Littrup PJ, Jaber M, Memon F, Adam B, Krycia M, Prus M, Heath E, Pontes E.
    J Vasc Interv Radiol; 2017 Oct; 28(10):1363-1370. PubMed ID: 28844831
    [Abstract] [Full Text] [Related]

  • 9. Salvage Percutaneous Cryoablation for Locally Recurrent Renal-Cell Carcinoma After Primary Cryoablation.
    Okhunov Z, Chamberlin J, Moreira DM, George A, Babaian K, Shah P, Youssef R, Kaler KS, Lobko II, Kavoussi L, Landman J.
    J Endourol; 2016 Jun; 30(6):632-7. PubMed ID: 27009377
    [Abstract] [Full Text] [Related]

  • 10. Radiofrequency Ablation, Cryoablation, and Microwave Ablation for T1a Renal Cell Carcinoma: A Comparative Evaluation of Therapeutic and Renal Function Outcomes.
    Zhou W, Herwald SE, McCarthy C, Uppot RN, Arellano RS.
    J Vasc Interv Radiol; 2019 Jul; 30(7):1035-1042. PubMed ID: 30956075
    [Abstract] [Full Text] [Related]

  • 11. Tumor Growth Kinetics and Oncologic Outcomes of Patients Undergoing Active Surveillance for Residual Renal Tumor following Percutaneous Thermal Ablation.
    Chen JX, Maass D, Guzzo TJ, Bruce Malkowicz S, Wein AJ, Soulen MC, Clark TWI, Nadolski GJ, William Stavropoulos S.
    J Vasc Interv Radiol; 2016 Sep; 27(9):1397-1406. PubMed ID: 27234485
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Percutaneous cryoablation of anterior renal masses: technique, efficacy, and safety.
    Schmit GD, Atwell TD, Leibovich BC, Callstrom MR, Kurup AN, Woodrum DA, Charboneau JW.
    AJR Am J Roentgenol; 2010 Dec; 195(6):1418-22. PubMed ID: 21098204
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thermal Ablation of T1c Renal Cell Carcinoma: A Comparative Assessment of Technical Performance, Procedural Outcome, and Safety of Microwave Ablation, Radiofrequency Ablation, and Cryoablation.
    Zhou W, Arellano RS.
    J Vasc Interv Radiol; 2018 Jul; 29(7):943-951. PubMed ID: 29628298
    [Abstract] [Full Text] [Related]

  • 16. Image-guided Cryoablation for Sporadic Renal Cell Carcinoma: Three- and 5-year Outcomes in 220 Patients with Biopsy-proven Renal Cell Carcinoma.
    Breen DJ, King AJ, Patel N, Lockyer R, Hayes M.
    Radiology; 2018 Nov; 289(2):554-561. PubMed ID: 30084744
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Development of a Risk-stratified Approach for Follow-up Imaging After Percutaneous Thermal Ablation of Sporadic Stage One Renal Cell Carcinoma.
    Dreyfuss LD, Wells SA, Best SL, Hedican SP, Ziemlewicz TJ, Lubner MG, Hinshaw JL, Lee FT, Nakada SY, Abel EJ.
    Urology; 2019 Dec; 134():148-153. PubMed ID: 31465794
    [Abstract] [Full Text] [Related]

  • 19. Percutaneous microwave ablation of T1a and T1b renal cell carcinoma: short-term efficacy and complications with emphasis on tumor complexity and single session treatment.
    Wells SA, Wheeler KM, Mithqal A, Patel MS, Brace CL, Schenkman NS.
    Abdom Radiol (NY); 2016 Jun; 41(6):1203-11. PubMed ID: 27167230
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.